Worth reading
47Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
61
Operating profit year on year (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPNet Sales46,769¥ millionYear on year +5.4%Progress 52.0%
Operating profit2,494¥ millionYear on year +61.0%Progress 62.4%
Ordinary income2,665¥ millionYear on year +74.5%Progress 66.6%
Net income attributable to owners of the parent1,658¥ millionYear on year +74.9%Progress 59.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥116.61
Financial position at period-end
Total assets83,708¥ million
of which net assets 45,203 ¥ millionEquity ratio 50.5%vs. prior year-end +0.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueFunctional Products Business ¥21,884 million (YoY +5.2%), Anti-Vibration Business ¥19,928 million (YoY +7.0%), Life Sciences Business ¥438 million (YoY -18.6%), Metal Processing Business ¥2,006 million (YoY -9.3%), Hose Business ¥2,948 million (YoY +13.4%)
Segment profitFunctional Products Business ¥2,505 million (YoY +15.2%), Anti-Vibration Business ¥1,531 million (YoY +33.4%), Life Sciences Business ¥79 million (YoY -38.5%), Metal Processing Business ¥92 million, Hose Business ¥375 million (YoY +78.4%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥90,000 million (YoY -0.0%)
Operating profit¥4,000 million (YoY +5.1%)
Ordinary income¥4,000 million (YoY +3.5%)
Net income¥2,800 million (YoY +144.6%)
Revision to Earnings ForecastNot disclosed → Net Sales 90,000 / Operating profit 4,000 / Ordinary income 4,000 / Net income 2,800
Annual Dividend Forecast¥85 per share → ¥100 per share（+17.6%）
Factors Behind Changes in Business Performance
Revenue from the Functional Products, Vibration Control and Hoses businesses remained strong. In addition to the increase in revenue, the benefits of higher productivity, efforts to optimise prices, and the reduction of loss-making, low-margin products outweighed the impact of increases in raw material, labour and other costs. The Life Science business was affected by lower orders from China for culture media and bags due to tighter regulations under China’s regenerative medicine system, while the Metal Processing business was affected by the selection and concentration of operations to improve profitability.
Disclosure regarding the going concern assumption
None
Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 None
Changes in the scope of consolidationNo material changes. The number and names of entities added to or removed from the scope are Not disclosed
Impairment lossNo applicable matters
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End15,909,130
Treasury Shares at Period-End1,679,842
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥46,769 million (YoY +5.4%) |
| Operating profit | ¥2,494 million (YoY +61.0%) |
| Ordinary income | ¥2,665 million (YoY +74.5%) |
| Profit attributable to owners of the parent | ¥1,658 million (YoY +74.9%) |
| Net income per share | ¥116.61 |
| Equity ratio | End of the current fiscal period 50.5 / End of previous period 50 |
| Total assets | ¥83,708 million |
| Net assets | ¥45,203 million |
| Full-year earnings forecast | Net Sales ¥90,000 million (YoY -0.0%) / Operating profit ¥4,000 million (YoY +5.1%) / Ordinary income ¥4,000 million (YoY +3.5%) / Net income ¥2,800 million (YoY +144.6%) |
| Revision to Earnings Forecast | Not disclosed → Net Sales 90,000 / Operating profit 4,000 / Ordinary income 4,000 / Net income 2,800 |
| Annual Dividend Forecast | ¥85 per share → ¥100 per share（+17.6%） |
| Segment revenue | Functional Products Business ¥21,884 million (YoY +5.2%), Anti-Vibration Business ¥19,928 million (YoY +7.0%), Life Sciences Business ¥438 million (YoY -18.6%), Metal Processing Business ¥2,006 million (YoY -9.3%), Hose Business ¥2,948 million (YoY +13.4%) |
| Segment profit | Functional Products Business ¥2,505 million (YoY +15.2%), Anti-Vibration Business ¥1,531 million (YoY +33.4%), Life Sciences Business ¥79 million (YoY -38.5%), Metal Processing Business ¥92 million, Hose Business ¥375 million (YoY +78.4%) |
| Impairment loss | No applicable matters |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | No material changes. The number and names of entities added to or removed from the scope are Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 15,909,130 |
| Treasury Shares at Period-End | 1,679,842 |
| Factors Behind Changes in Business Performance | Revenue from the Functional Products, Vibration Control and Hoses businesses remained strong. In addition to the increase in revenue, the benefits of higher productivity, efforts to optimise prices, and the reduction of loss-making, low-margin products outweighed the impact of increases in raw material, labour and other costs. The Life Science business was affected by lower orders from China for culture media and bags due to tighter regulations under China’s regenerative medicine system, while the Metal Processing business was affected by the selection and concentration of operations to improve profitability. |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogDepreciation and amortizationBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to the increase in revenue, the benefits of higher productivity, efforts to optimise prices, and the reduction of loss-making, low-margin products outweighed the impact of increases in raw material, labour and other costs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.